Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtains drug registration certificate for Sacubitril Valsartan Sodium Tablets.
Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Shandong Lukang Pharmaceutical (600789.SH) announced that recently, its controlling subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for Sacubitril Valsartan Sodium Tablets. This drug is a generic drug approved under new registration category 4, and is deemed to have passed the consistency evaluation of generic drug quality and efficacy. The drug is used for the treatment of chronic heart failure with reduced ejection fraction and essential hypertension.
Related Articles
Anhui Fengyuan Pharmaceutical (000153.SZ) subsidiary's tirofiban hydrochloride API approved for marketing
YUEXIU PROPERTY (00123) has been granted a HK$300 million term loan facility.
UBS Group AG (UBS.US) CEO Gives Early "Spoiler" on Q3 Results: Wealth Management Business Has Good Momentum, but Growth Will Be Lower Than Last Year
Anhui Fengyuan Pharmaceutical (000153.SZ) subsidiary's tirofiban hydrochloride API approved for marketing
YUEXIU PROPERTY (00123) has been granted a HK$300 million term loan facility.
UBS Group AG (UBS.US) CEO Gives Early "Spoiler" on Q3 Results: Wealth Management Business Has Good Momentum, but Growth Will Be Lower Than Last Year
